Biotinylated Human CD79B Protein
Catalog No: CD79B-HB002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CD79B Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ala29-Asp159 (UniProt accession: P40259-1).
Product Details
- Molecular Aliases
- B29; CD79b molecule; CD79B; IGB; IGBAGM6; Ig-beta; Ig-β; Ig-b
- Protein Length
- Ala29-Asp159
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 18.1 kDa. Due to glycosylation, the protein migrates to 35-45 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 24 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated CD79B on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated CD79B is greater than 95% as determined by SEC-HPLC.
Immobilized Polatuzumab, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Human CD79B, His Tag with the EC50 of 23.4 ng/ml determined by ELISA.
Background
CD79B (also known as B29, Ig beta and B cell antigen receptor complex-associated protein beta-chain) is a 36-40 kDa member of the Ig-Superfamily. It is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
References
- Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma[J]. Blood, 2009, 114(13):2721-2729.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.